Literature DB >> 8097934

Synergistic effects of interleukin 4 and interleukin 12 on NK cell proliferation.

B Naume1, M K Gately, B B Desai, A Sundan, T Espevik.   

Abstract

Our previous studies have demonstrated that interleukin12 (IL-12) (cytotoxic lymphocyte maturation factor/NK cell stimulatory factor) and IL-7 alone have the ability to generate high LAK activity and low proliferative activity in CD56+ NK cells. This study was undertaken to examine the influence of IL-4 on the IL-12-induced activation of CD56+ NK cells. IL-4 did not affect the IL-12-induced generation of LAK activity in CD56+ cells, in contrast to an inhibition of IL-2 and IL-7-induced LAK activity. Most interestingly, the combination of IL-4 and IL-12 resulted in a synergistic proliferative activity (8-fold) in the CD56+ NK cells, and a marked increase in the cell yield at day 5 was detected. Furthermore, the potent effect of IL-4 on IL-12-induced proliferation was restricted to the CD56+ NK cells, as CD56- cell populations were found unresponsive to the combination of IL-4 and IL-12. Furthermore, IL-4 induced a slight increase in the IL-12-stimulated TNF production. IL-12 enhanced the IL-12 receptor (R) expression and IL-4R expression in the CD56+ NK cells. Combined treatment with IL-12 and IL-4 further enhanced the IL-12R expression, most prominently in the CD56+, CD16- NK subpopulation. The increased IL-4R expression induced by IL-12 and the increased IL-12R expression induced by IL-4 may explain the synergistic proliferative activity detected in response to IL-12 and IL-4. IL-4 seems to possess unique stimulatory properties towards resting CD56+ NK cells, when used as a costimulus with IL-12.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8097934     DOI: 10.1016/1043-4666(93)90022-w

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  8 in total

1.  Interleukin 12 induces the differentiation of major histocompatibility complex class I-primed cytotoxic T-lymphocyte precursors into allospecific cytotoxic effectors.

Authors:  S Chouaib; J Chehimi; L Bani; N Genetet; T Tursz; F Gay; G Trinchieri; F Mami-Chouaib
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-20       Impact factor: 11.205

Review 2.  Interleukin-12: a bridge between innate resistance and adaptive immunity with a role in infection and acquired immunodeficiency.

Authors:  J Chehimi; G Trinchieri
Journal:  J Clin Immunol       Date:  1994-05       Impact factor: 8.317

Review 3.  Interleukin-12: potential clinical applications in the treatment and prevention of infectious diseases.

Authors:  M K Gately; M J Mulqueen
Journal:  Drugs       Date:  1996       Impact factor: 9.546

Review 4.  The potential for genetically altered microglia to influence glioma treatment.

Authors:  W Li; R M D Holsinger; C A Kruse; A Flügel; M B Graeber
Journal:  CNS Neurol Disord Drug Targets       Date:  2013-09       Impact factor: 4.388

Review 5.  Natural killer cells and antifungal host response.

Authors:  Stanislaw Schmidt; Stefanie-Yvonne Zimmermann; Lars Tramsen; Ulrike Koehl; Thomas Lehrnbecher
Journal:  Clin Vaccine Immunol       Date:  2013-01-30

6.  Circulating Tumor Cells (CTC) Are Associated with Defects in Adaptive Immunity in Patients with Inflammatory Breast Cancer.

Authors:  M Mego; H Gao; E N Cohen; S Anfossi; A Giordano; T Sanda; T M Fouad; U De Giorgi; M Giuliano; W A Woodward; R H Alvarez; V Valero; N T Ueno; G N Hortobagyi; M Cristofanilli; J M Reuben
Journal:  J Cancer       Date:  2016-06-03       Impact factor: 4.207

7.  Characterization of the interaction between human decidua parietalis mesenchymal stem/stromal cells and natural killer cells.

Authors:  M H Abumaree; E Bahattab; A Alsadoun; A Al Dosaimani; F M Abomaray; T Khatlani; B Kalionis; M F El-Muzaini; A O Alawad; A S AlAskar
Journal:  Stem Cell Res Ther       Date:  2018-04-12       Impact factor: 6.832

8.  Interleukin 12 synergizes with B7/CD28 interaction in inducing efficient proliferation and cytokine production of human T cells.

Authors:  M Kubin; M Kamoun; G Trinchieri
Journal:  J Exp Med       Date:  1994-07-01       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.